Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metreleptin for Multiple Symmetric Lipomatosis (MSL)
NCT05351164Phase 2Active, not recruiting
- Sponsor
- University of Michigan
- Start
- Aug 2023
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metreleptin in multiple symmetric lipomatosis (MSL), sponsored by University of Michigan. Primary endpoints: Change in Truncal Adiposity at 24 weeks and Change in Total Adiposity at 24 weeks. Started Aug 2023; status: active, not recruiting.
02
Drugs
metreleptin
03
Conditions
multiple symmetric lipomatosis (MSL)
Beyond the preview
Go deeper on NCT05351164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351164.